September 30, 2020
Enrolment: The meeting is designed for scientist and consultants
This meeting is designed as a unique space to share ideas and data on MRI contrast agent research and possible gadolinium toxicity after the administration of gadolinium-based contrast agents (GBCAs). We believe that joint international efforts will remain essential to optimize diagnostic efficacy and improve patient safety in MR imaging.
After the European Medicines Agency (EMA) recommended the suspension of the marketing authorization for high-risk GBCAs, the European landscape has changed significantly. Despite the recognition that linear GBCAs are depositing more gadolinium than macrocyclic GBCAs, no health effects have been associated with either class of agents.
This 5th GREC meeting will address some relevant issues related to the use of GBCAs in MRI, such as its effect in the environment, the potential clinical/histological consequences of their use in humans and animals, the development of a new-generation of high-relaxivity gadolinium chelates and of new non-GBCAs, and the implementation of strategies to reduce the use of GBCAs in different clinical situations.
We look forward to seeing you online!
Institutional Scientific Patronage provided by ESMRMB.
- To present state of the research on:
- gadolinium deposition and related GBCA toxicity issues
- GBCA alternatives and solutions for Gadolinium-free MRI
- Sustainable GBCA use and GBCA in the environment
- To further develop and improve preclinical and clinical GBCA research
- To provide guidelines and recommendations on the use of GBCAs
CLICK HERE to browse the online programme.
Registration is available here. Registration will only be available as a full congress ticket to ESMRMB 2020, i.e. including Oct. 1 and 2, 2020.
Please contact us at email@example.com for any questions related to the ESMRMB-GREC 2020 meeting registration or by phone at (+43) 1 533 4064 915.